Jobevne Injection
NDC Package 83257-009-11
Package Information
Jobevne (bevacizumab-nwgd) injection is a medication a man-made antibody (IgG1) used to treat various types of cancer. This formulation utilizes a injection delivery system. Marketed by Biocon Biologics Inc., this product is identified by NDC 83257-009 and is authorized under FDA application BLA761175.
Identification & Billing
- RxCUI: 2712048 - bevacizumab-nwgd 100 MG in 4 ML Injection
- RxCUI: 2712048 - 4 ML bevacizumab-nwgd 25 MG/ML Injection
- RxCUI: 2712048 - bevacizumab-nwgd 100 MG per 4 ML Injection
- RxCUI: 2712055 - Jobevne 100 MG in 4 ML Injection
- RxCUI: 2712055 - 4 ML bevacizumab-nwgd 25 MG/ML Injection [Jobevne]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 83257 - Biocon Biologics Inc.
- 83257-009 - Jobevne
- 83257-009-11 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 4 mL in 1 VIAL, SINGLE-DOSE
- 83257-009 - Jobevne
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83257-009-11 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 4 ml in 1 vial, single-dose of Jobevne, a human prescription drug labeled by Biocon Biologics Inc.. This injection is formulated for intravascular use and contains bevacizumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Biocon Biologics Inc. on April 10, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-awwb, and bevacizumab-bvzr.
How is this Biocon Biologics Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83257000911. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
